{"groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"FG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"17"}],"type":"Started new therapies"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Due to progression of disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Due to lack of response"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"80"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was conducted across 14 countries (the USA, France, Italy, Germany, Belgium, Canada, Czech Republic, Ireland, Israel, Norway, Poland, Serbia, Spain, and United Kingdom)."}